Hicure Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 04-10-2024
- Paid Up Capital ₹ 1.45 Cr
as on 04-10-2024
- Company Age 21 Year, 6 Months
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 11.37 Cr
as on 04-10-2024
- Revenue -26.69%
(FY 2019)
- Profit 26.70%
(FY 2019)
- Ebitda 8.24%
(FY 2019)
- Net Worth -306.57%
(FY 2019)
- Total Assets 17.74%
(FY 2019)
About Hicure Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.45 Cr.
The company has closed loans amounting to ₹11.37 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Meghashyam Ladhad and Rahul Nagmule serve as directors at the Company.
- CIN/LLPIN
U24231KA2003PTC032145
- Company No.
032145
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2003
- Date of AGM
23 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Dharwad, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hicure Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meghashyam Ladhad  | Director | 17-Nov-2011 | Current |
| Rahul Nagmule | Director | 17-Nov-2011 | Current |
Financial Performance of Hicure Pharmaceuticals.
Hicure Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 26.69% decrease. The company also saw a substantial improvement in profitability, with a 26.7% increase in profit. The company's net worth observed a substantial decline by a decrease of 306.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hicure Pharmaceuticals?
In 2019, Hicure Pharmaceuticals had a promoter holding of 29.56% and a public holding of 70.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sha Kanji Devji Refineries Private LimitedActive 38 years 25 daysMeghashyam Ladhad is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 22 Sep 2016 | ₹6.50 M | Satisfied |
Others Creation Date: 05 May 2016 | ₹1.00 Cr | Satisfied |
Syndicate Bank Creation Date: 05 Dec 2014 | ₹3.75 Cr | Satisfied |
How Many Employees Work at Hicure Pharmaceuticals?
Unlock and access historical data on people associated with Hicure Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hicure Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hicure Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
